Deadly brain cancer shrinks after CAR-T therapy — but for how long is unclear Early studies with engineered immune cells show drastic but often short-lived results in glioblastoma, the most aggressive brain cancer. By Heidi Ledford

Deadly brain cancer shrinks after CAR-T therapy — but for how long is unclear Early studies with engineered immune cells show drastic but often short-lived results in glioblastoma, the most aggressive brain cancer. By Heidi Ledford https://www.nature.com/articles/d41586-024-00704-6?utm_source=Live+Audience&utm_campaign=68f5e9ceab-briefing-dy-20240318&utm_medium=email&utm_term=0_b27a691814-68f5e9ceab-50432164